Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Sep 8 - Sep 10, 201921ST ANNUAL GLOBAL INVESTMENT CONFERENCE
May 31 - Jun 4, 2019AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 31, 2019SACHS ASSOCIATES 5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM